{"id":"NCT02075255","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy","officialTitle":"A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) to Reduce Oral Corticosteroid Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy (ZONDA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04-28","primaryCompletion":"2016-08-08","completion":"2016-08-08","firstPosted":"2014-03-03","resultsPosted":"2017-10-17","lastUpdate":"2018-06-08"},"enrollment":220,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"BIOLOGICAL","name":"Benralizumab","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"Benralizumab","otherNames":[]}],"arms":[{"label":"Benralizumab Arm A","type":"EXPERIMENTAL"},{"label":"Benralizumab Arm B","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this trial is to confirm if benralizumab can reduce the use of maintenance OCS in systemic corticosteroid dependent patients with severe refractory asthma with elevated eosinophils.","primaryOutcome":{"measure":"Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control","timeFrame":"Week 28","effectByArm":[{"arm":"Benralizumab 30 mg q.4 Weeks","deltaMin":75,"sd":null},{"arm":"Benralizumab 30 mg q.8 Weeks","deltaMin":75,"sd":null},{"arm":"Placebo","deltaMin":25,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":87,"countries":["United States","Argentina","Bulgaria","Canada","Chile","France","Germany","Poland","South Korea","Spain","Turkey (Türkiye)","Ukraine"]},"refs":{"pmids":["28530840","35287231","31579676","30802500"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2559&filename=Nair_ZONDA_CSP_REDACTED.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":72},"commonTop":["Nasopharyngitis","Bronchitis","Asthma","Sinusitis","Headache"]}}